

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of 10

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1040 1647
Examiner Name	Unassigned - Nichols
Attorney Docket Number	15270J005910

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
2	196	6,150,081		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	2	5,958,883		Snow	09-28-1999	
	3	5,955,317		Suzuki et al.	09-21-1999	
	4	5,955,079		Mond et al.	08-21-1999	
	5	5,877,399		Hsiao et al.	03-02-1999	
	6	5,869,093		Weiner et al.	02-09-1999	
	7	5,869,054		Weiner et al.	02-09-1999	
	8	5,854,204		Findeis et al.	12-29-1998	
	9	5,851,996		Kline	12-22-1998	
	10	5,849,298		Weiner et al.	12-15-1998	
	11	5,837,473		Maggio et al.	11-17-1998	
	12	5,786,180		Konig et al.	07-28-1998	
	13	5,753,624		McMichael et al.	05-19-1998	
	14	5,750,349		Suzuki et al.	05-12-1998	
	107	5,744,368		Goldhaber et al.	04-28-1998	
	15	5,733,547		Weiner et al.	03-31-1998	
	16	5,688,651		Solomon	11-18-1997	
	17	5,679,348		Nesburn et al.	10-21-1997	
	18	5,645,820		Hafler et al.	07-08-1997	
	19	5,641,474		Hafler et al.	06-24-1997	
	20	5,641,473		Hafler et al.	06-24-1997	
	21	5,642,486		McConlogue et al.	03-18-1997	
	22	5,605,811		Seubert et al.	02-25-1997	
	23	5,585,100		Mond et al.	12-17-1996	
	24	5,571,500		Hafler et al.	11-05-1996	
	25	5,571,499		Hafler et al.	11-05-1996	
	175	5,441,870		Seubert et al.	08-15-1995	
	26	5,434,170		Andrulis, Jr.	07-18-1995	

Examiner Signature

Julius

Date Considered

11/24/03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

RECEIVED

RECEIVED

MAY 16 2002

TECH CENTER 160012900

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	4846-1647
Examiner Name	Unassigned NICHOLES
Attorney Docket Number	15270J005910

COPY

U.S. PATENT DOCUMENTS

27	5,387,742	Cordell	02-07-1985
181	5,270,183	Van Nostrand et al.	12-14-1993
28	5,231,000	Majocha et al.	07-27-1993
29	5,220,013	Ponte et al.	06-15-1993
30	5,208,036	Eppstein et al.	05-04-1993
31	5,192,753	McGeer et al.	03-09-1993
32	5,187,153	Cordell et al.	02-18-93
33	5,057,540	Kensil et al.	10-15-1991
188	5,004,897	Pardridge	04-02-1991
34	4,666,620	Glenner et al.	05-16-1987

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
CSW	35	EP	911 036	A2		04-28-1999		<input type="checkbox"/>
	36	EP	868 918	A2		10-07-1998		<input type="checkbox"/>
	37	EP	863 211	A1		09-09-1998		<input type="checkbox"/>
	38	EP	845 270	A1		06-03-1998		<input type="checkbox"/>
	39	EP	782 859	A1		07-08-1997		<input type="checkbox"/>
	40	EP	683 234	A1		11-22-1995		<input type="checkbox"/>
	41	EP	666 080	A1		08-09-1995		<input type="checkbox"/>
	42	EP	652 962	B1		12-16-1998		<input type="checkbox"/>
	43	EP	639 081	B1		11-03-1999		<input type="checkbox"/>
	44	EP	613 007	A2		08-31-1994		<input type="checkbox"/>
	45	EP	594 607	B1		08-27-1997		<input type="checkbox"/>
	46	EP	581 087	B1		08-04-1999		<input type="checkbox"/>
	47	EP	526 511	B1		05-26-1997		<input type="checkbox"/>
	48	EP	508 785	B1		03-15-2000		<input type="checkbox"/>
	49	EP	451 700	A1		10-16-1991		<input type="checkbox"/>
V	50	EP	440 619	B1		01-24-1996		<input type="checkbox"/>
	51	EP	359 783	B1		11-29-1995		<input type="checkbox"/>
	52	EP	276 723	B1		12-08-1993		<input type="checkbox"/>
	187	EP	783 104	A1		07-09-1997		<input type="checkbox"/>
	189	PCT	00/77178	A1		12-21-2000		<input type="checkbox"/>
CSW	188	PCT	00/43049	A1		07-27-2000		<input type="checkbox"/>
	53	PCT	99/80024	A1		11-25-1999		<input type="checkbox"/>

Examiner Signature

Date Considered

9/9/04

*EXAMINER: Initial if reference considered, whether or not citation is in compliance with MPEP 809. Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
PA 3142468 v1

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002: OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1846-1647
Examiner Name	Unassigned - NICHOLS
Attorney Docket Number	15270J005910

Sheet 3 of 10

56	PCT	99/06066	A2		02-11-1999	
57	PCT	99/27949	A1		06-10-1999	
58	PCT	99/27944	A1		06-10-1999	
59	PCT	99/27911	A1		06-10-1999	
60	PCT	98/44955	A1		10-15-1998	
61	PCT	98/07850	A2		02-26-1998	
62	PCT	97/17613	A1		05-15-1997	
63	PCT	96/39176	A1		12-12-1996	
64	PCT	96/35435	A1		08-22-1996	
65	PCT	96/18980	A1		06-20-1996	
66	PCT	95/31996	A1		11-30-1995	
200	PCT	95/12815	A1		05-11-1995	
67	PCT	95/11994	A1		05-04-1995	
68	PCT	95/11311	A1		04-27-1995	
69	PCT	95/05853	A1		03-02-1995	
70	PCT	95/04151	A2		02-09-1995	
71	PCT	94/03615	A1		02-17-1994	
72	PCT	94/01772	A1		01-20-1994	
73	PCT	93/21950	A1		11-11-1993	
74	PCT	93/16724	A1		09-02-1993	
75	PCT	93/15760	A1		08-19-1993	
76	PCT	93/14200	A1		07-22-1993	
77	PCT	93/02189	A1		02-04-1993	
78	PCT	92/13069	A1		08-06-1992	
79	PCT	92/06708	A1		04-30-1992	
80	PCT	92/06187	A1		04-16-1992	
81	PCT	91/19810	A1		12-26-1991	
82	PCT	91/16819	A1		11-14-1991	
83	PCT	91/12816	A1		09-05-1991	
84	PCT	91/08760	A1		06-27-1991	
85	PCT	90/12871	A1		11-01-1990	
86	PCT	90/12870	A1		11-01-1990	
87	PCT	89/01343	A1		02-23-1989	
88	PCT	89/06242	A1		07-13-1989	
89	PCT	89/06689	A1		07-27-1989	
90	PCT	89/03687	A1		05-05-1989	
91	PCT	88/10120	A1		12-29-1988	
92	GB	2 220 211	A		01-04-1990	
93	GB	2 335 192	A		09-15-1999	


CONSIDERED.

Examiner Signature	<i>G. Nichols</i>	Date Considered	11/24/03
--------------------	-------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1040 <u>1648</u>
Examiner Name	Unassigned <u>NIENHUIS</u>
Attorney Docket Number	15270J005910

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<u>CSW</u>	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," <u>Neurology</u> , 45:1441-1445 (1995).	<input checked="" type="checkbox"/>
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95).	<input checked="" type="checkbox"/>
	96	BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).	<input checked="" type="checkbox"/>
	176	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).	<input checked="" type="checkbox"/>
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999).	<input checked="" type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).	<input checked="" type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).	<input checked="" type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genet. Develop.</u> , 3: 102-109 (1993).	<input checked="" type="checkbox"/>
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).	<input checked="" type="checkbox"/>
	102	CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513.7 (1993).	<input checked="" type="checkbox"/>
	103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995).	<input checked="" type="checkbox"/>
	104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).	<input checked="" type="checkbox"/>
<u>V</u>	105	ELSENSTEIN et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).	<input checked="" type="checkbox"/>
<u>CSW</u>	106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).	<input checked="" type="checkbox"/>

Examiner Signature	<u>G. Nienhuis</u>	Date Considered	<u>11/24/03</u>
--------------------	--------------------	-----------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	4646 1647
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	15270J005910

Sheet 5 of 10

<u>CSO</u>	107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).	<input type="checkbox"/>
	108	FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).	<input type="checkbox"/>
	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).	<input type="checkbox"/>
	110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).	<input type="checkbox"/>
	111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).	<input type="checkbox"/>
	112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998).	<input type="checkbox"/>
	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).	<input type="checkbox"/>
	114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).	<input type="checkbox"/>
	115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).	<input type="checkbox"/>
	116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996).	<input type="checkbox"/>
	190	GRAVINA et al., "Amyloid β Protein ($A\beta$) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).	<input type="checkbox"/>
	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).	<input type="checkbox"/>
	118	HAGA et al., "Synthetic Alzheimer amyloid $\beta/A4$ peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).	<input type="checkbox"/>
	119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	<input type="checkbox"/>
<u>✓</u>	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	<input type="checkbox"/>
<u>CSH</u>	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).	<input type="checkbox"/>

Examiner
Signature

Date
Considered

11/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 10

Complete If Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1640 1647
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	15270J005910

C30	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <i>Biophysica Acta</i> , 1158:120-128 (1993).	<input type="checkbox"/>
	177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <i>Science</i> , 289:375 (2000).	<input type="checkbox"/>
	122	HISIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 274: 99-102 (1996).	<input type="checkbox"/>
	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <i>J. Neuroimmunology</i> , 52:147-152 (1994).	<input type="checkbox"/>
	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <i>N. E. J. Medicine</i> , 333(19):1283-1284 (1995).	<input type="checkbox"/>
	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <i>J. Neuroimmunology</i> , 24:173-182 (1989).	<input type="checkbox"/>
	192	IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <i>Neuron</i> , 13:45-53 (1994).	<input type="checkbox"/>
	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <i>Immun. Rev.</i> , 62: 185-216 (1982).	<input type="checkbox"/>
	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <i>Res. Immunology</i> , 143:637-641 (1992).	<input type="checkbox"/>
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <i>Biotechnol. Appl. Biochem.</i> , 23:227-230 (1996).	<input type="checkbox"/>
	128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <i>Nature</i> , 354:476-478 (1991).	<input type="checkbox"/>
	155	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2D Specific for the Carboxyl-Terminus of the β A4 Peptide," <i>Annals of NY Acad. Sci.</i> , 777:344-355 (1996).	<input type="checkbox"/>
	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <i>Neurodegeneration</i> , 2:111-121 (1993).	<input type="checkbox"/>
	130	LANGER, "New Methods of Drug Delivery," <i>Science</i> , 249: 1527-1532 (1990).	<input type="checkbox"/>
	131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <i>Behavioural Brain Res.</i> , 57:207-213 (1993).	<input type="checkbox"/>
	132	LEMIERE et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-Ap Transgenic Mice," <i>Society for Neuroscience Abstracts</i> , vol. 25, part 1, Abstract 519.6, 29th Annual Meeting, October 23-28, 1999.	<input type="checkbox"/>
C30	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <i>J. Immunol.</i> , 159: 1383-1392 (1997).	<input type="checkbox"/>

Examiner
Signature

Date
Considered

11/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1040 1047
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	15270J005910

Sheet 7 of 10

134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <i>Acta. Neurol. Scand.</i> , 84:441-444 (1991).	<input type="checkbox"/>
135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <i>J. Micro. Encap.</i> , 14(2): 197-210 (1997).	<input type="checkbox"/>
136	MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <i>Nature</i> , 374:647-650 (1995).	<input type="checkbox"/>
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <i>J. Exp. Med.</i> , 174:791-798 (1991).	<input type="checkbox"/>
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <i>Am. J. Pathology</i> , 144(5):1082-1088 (1994).	<input type="checkbox"/>
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <i>Am. J. Epidemiol.</i> , 145(11): 959-969 (June 1, 1997).	<input type="checkbox"/>
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	<input type="checkbox"/>
140	PARESE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <i>Neuron</i> , 17:553-565 (September 1996).	<input type="checkbox"/>
141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <i>Eur. J. Immunol.</i> , 25: 3521-3524 (1995).	<input type="checkbox"/>
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <i>Chemical Abstracts</i> , 120(8) pg. 652, column 1, abstract 86406t (1994).	<input type="checkbox"/>
143	QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <i>Nature</i> , 352:239-241 (1991).	<input type="checkbox"/>
144	RASO, V.A., Grant application # 1 R43 AG1 5746-01 (publication date unknown).	<input type="checkbox"/>
145	RASO, "Immunotherapy of Alzheimer's Disease," <i>Immunotherapy Weekly</i> , Abstract (April 12, 1998).	<input type="checkbox"/>
146	ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <i>PNAS</i> , 89:1-5 (1992).	<input type="checkbox"/>
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <i>Annals of New York Academy of Sciences</i> , 695:198-202 (1993).	<input type="checkbox"/>
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <i>J. Biol. Chem.</i> , 268(33):25239-25243 (1993).	<input type="checkbox"/>
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <i>J. Biol. Chem.</i> , 269(21):15253-15257 (1994).	<input type="checkbox"/>

CONSIDERED

Examiner
Signature

Date
Considered

11/24/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1640-1647
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	15270J005910

<input checked="" type="checkbox"/>	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	<input type="checkbox"/>
<input type="checkbox"/>	148	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	<input type="checkbox"/>
<input type="checkbox"/>	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	<input type="checkbox"/>
<input type="checkbox"/>	160	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	<input type="checkbox"/>
<input type="checkbox"/>	151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	<input type="checkbox"/>
<input type="checkbox"/>	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November 1991).	<input type="checkbox"/>
<input type="checkbox"/>	153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	<input type="checkbox"/>
<input type="checkbox"/>	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	<input type="checkbox"/>
<input type="checkbox"/>	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	<input type="checkbox"/>
<input type="checkbox"/>	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	<input type="checkbox"/>
<input type="checkbox"/>	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	<input type="checkbox"/>
<input type="checkbox"/>	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	<input type="checkbox"/>
<input type="checkbox"/>	159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).	<input type="checkbox"/>
<input type="checkbox"/>	160	SOLOMON et al., "Monoclonal antibodies inhibit <i>in vitro</i> fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).	<input type="checkbox"/>
<input type="checkbox"/>	161	SOLOMON, A., "Pro-RX (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).	<input type="checkbox"/>
<input type="checkbox"/>	182	SOLOMON, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel.	<input type="checkbox"/>
<input checked="" type="checkbox"/>	182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	<input type="checkbox"/>

considered; DO NOT PRINT #161+162.

Examiner Signature		Date Considered	11/24/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/06A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known

Application Number 09/585,817
Filing Date June 1, 2000
First Named Inventor Schenk, Dale B.
Group Art Unit 1648-1647
Examiner Name Unassigned NICHOLS
Attorney Docket Number 15270J005910

184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <i>Biochem. Mol. Biol. Int.</i> , 43(3):601-611 (1997).	<input type="checkbox"/>
185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <i>Adv. Mol. Cell Biology</i> , 15A:33-45 (1996).	<input type="checkbox"/>
186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).	<input type="checkbox"/>
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <i>J. Neurochemistry</i> , 66:259-265 (1996).	<input type="checkbox"/>
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria," <i>N. Engl. J. Med.</i> , 336(2): 86-91 (1997).	<input type="checkbox"/>
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>PNAS</i> , 94: 13287-13292 (1997).	<input type="checkbox"/>
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <i>European J. Pharmacology</i> , 352:135-142 (1998).	<input type="checkbox"/>
166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37, (1994).	<input type="checkbox"/>
167	VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neuroscience Letters</i> , 172:122-124 (1994).	<input type="checkbox"/>
168	VERBEEK et al., "Accumulation of Interleukin Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Journ. Pathology</i> , 144(1):104-116 (1994).	<input type="checkbox"/>
169	WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurology</i> , 53(4):377-383 (1994).	<input type="checkbox"/>
180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <i>J. Food Drug Analysis</i> , 6(2):465-476 (1998).	<input type="checkbox"/>
170	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <i>Nature Biotech.</i> , 18:868-824 (2000).	<input type="checkbox"/>
171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994).	<input type="checkbox"/>
172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <i>Curr. Opin. Neurobiol.</i> , 7: 695-700 (1997).	<input type="checkbox"/>
173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS</i> , 94: 1550-1555 (1997).	<input type="checkbox"/>

Examiner
Signature

[Handwritten Signature]

Date
Considered

11/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

COPY NOT PRINT # 186.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 10

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1046 1647
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	15270J005910

174	Human Immunology & Cancer Program brochure from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	<input checked="" type="checkbox"/>
		<input type="checkbox"/>

PA 3142468 v1

CONSIDERED; DO NOT PRINT # 174.

Examiner Signature		Date Considered	11/24/03
-----------------------	--	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231